-
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript
12 May 2024 05:12 GMT
… and welcome to Cumberland Pharmaceuticals First Quarter 2024 Financial … approved by the FDA for the treatment of hospital-acquired … cardiomyopathy associated with Duchenne Muscular Dystrophy, or DMD, a … sponsoring that FIGHT DMD trial, which is a multicenter …
-
Rabbi Yosef Zvi Rimon: Influencing the fate of millions with muscular dystrophy
11 May 2024 01:11 GMT
… parents whose children have Duchenne muscular dystrophy (DMD). These parents brought … future medication. Ultimately, the committee rejected the use of this particular drug … better than a treatment currently in use.”
Does the pharmaceutical committee need …
-
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced
11 May 2024 13:08 GMT
… phase 2b PARADIGM trial showed that treatment with PrimeC (NeuroSense … ) in boys with Duchenne muscular dystrophy (DMD) has suddenly passed … the FDA’s Peripheral and Central Nervous System Drugs Advisory … to discuss the new drug application of donanemab, an …
-
Boy Receives Experimental Therapy for Duchenne Muscular Dystrophy, Passes Away
09 May 2024 14:30 GMT
… potential therapies to treat all forms of muscular dystrophy.
RENO, NV … in a clinical trial for Duchenne muscular dystrophy from a … of high-quality, effective medications. We strive to … development of our promising drug treatments for muscle diseases. …
-
FDA Grants Breakthrough Therapy Designation for AOC 1001 in Myotonic Dystrophy Type 1
10 May 2024 22:06 GMT
… to a recent announcement, the FDA has granted breakthrough therapy designation … trial (NCT05479981) which further highlighted AOC 1001’s potential as a treatment … recently presented at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific …
-
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2024 Earnings Call Transcript
10 May 2024 21:52 GMT
… and welcome to the Catalyst Pharmaceuticals’ First Quarter 2024 Financial … launched AGAMREE for Duchenne Muscular Dystrophy of DMD on March … traditional steroid use in treating DMD is in the … more patients being eligible for treatment with FIRDAPSE. Now, let …
-
Sarcomatrix Acquires Recombinant Human Laminin-111: A Promising Candidate for Treating LAMA2-RD Muscular Dystrophies
10 May 2024 14:15 GMT
… therapy, rhLaminin-111, aimed at treating LAMA2-Related Dystrophies, a rare … Sarcomatrix at the forefront of muscular dystrophy research.
The portfolio of intellectual … the development of our promising drug treatments
for muscle diseases. We are …
-
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
08 May 2024 12:00 GMT
… 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD … Drug Administration (FDA) Fast Track designation and Orphan Drug Designation for the treatment … drug targets that can modulate gene expression to treat the …
-
Cell and Gene Therapies in CNS Disorders Research Report 2024: Pricing and Reimbursement Assessment, Current Treatment Options, Likelihood of Approval and Phase, Future Sales - Forecasts to 2029 - ResearchAndMarkets.com
10 May 2024 12:43 GMT
… (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA … deficiency (AADCD), and Duchenne muscular dystrophy (DMD).
Reasons to Buy
… Executive Summary
3. Current Treatment Options
3.1. What … the 8MM
5.2. FDA Guidance for Industry - Human …
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
09 May 2024 20:09 GMT
… of a clinical trial for patients … be effective in treating your diagnosis or … treatment for type 1 myotonic dystrophy, the most common adult-onset muscular dystrophy … Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable …